Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02477748
Recruitment Status : Terminated (FDA Clinical hold)
First Posted : June 23, 2015
Last Update Posted : January 19, 2017
Sponsor:
Information provided by (Responsible Party):
Alcobra Ltd.

Brief Summary:

This study is a multi-center, randomized, double-blind, placebo-controlled, phase 3 study of MDX (1400 mg daily) for 10 weeks compared with placebo in adults with ADHD.

The study will be comprised of Screening, Washout (if required), Treatment (total of 10 weeks) and Follow-up periods. Approximately 750 patients will be enrolled and undergo initial eligibility assessments.


Condition or disease Intervention/treatment Phase
Attention Deficit Hyperactivity Disorder (ADHD) Drug: MDX Drug: Placebo Phase 3

Detailed Description:
  • A 10-week randomized, multi-center, double-blind, placebo-controlled, phase 3 study of MDX (1400 mg daily) for 10 weeks compared with placebo in adults with ADHD.
  • The study will be comprised of Screening, Washout (if required), Treatment (total of 10 weeks) and Follow-up periods. Approximately 750 patients will be enrolled and undergo initial eligibility assessments.
  • Subjects requiring a washout will undergo a Washout period where ADHD medication is discontinued (21 days for atomoxetine, 14 days for other ADHD medications). These subjects will have an Interim Visit (off drug) on or about Day -10 (Day -10 to Day -3) for CAARS-Inv assessment at the end of the Washout period.
  • Subjects will be randomly assigned to placebo/MDX for a total treatment duration of up to ten weeks.

There will be a one week Follow-up period after the last dose of study treatment or early termination.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 283 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Study Start Date : June 2015
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: MDX
Metadoxine Immediate-release/slow-release, bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.; alternative name: MG01CI.
Drug: MDX
Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
Other Name: MG01CI

Placebo Comparator: Placebo
Inert tablets
Drug: Placebo
Tablet PO, taken once daily for 10 weeks.
Other Name: Inert tablet




Primary Outcome Measures :
  1. 18-item total ADHD symptom score of the Conners Adult ADHD Rating Scale:O-SV (with the investigator as observer) with adult ADHD prompts (CAARS investigator). [ Time Frame: 10 weeks ]
    The scale will be analyzed by change from Baseline to Week 10.


Secondary Outcome Measures :
  1. Questionnaires of Clinical Global Severity of Illness (CGI-S) and Clinical Global Improvement (CGI-I). [ Time Frame: 10 weeks ]
    The questionnaires will be analyzed by change from Baseline to all visits as well as by response rates.

  2. Adult ADHD Self Report Scale (ASRS-Self) v1.1 Symptom Checklist - expanded version [ Time Frame: 10 weeks ]
    The scale will be analyzed by change from Baseline to Week 10 in total score and sub- scales.

  3. Test of Variables of Attention (TOVA) [ Time Frame: 10 weeks ]
    A continuous performance test performed on the computer. Change from Baseline and response rate of Attention Comparison Score (ACS) will be assessed.

  4. Test of Variables of Attention (TOVA) [ Time Frame: 10 weeks ]
    A continuous performance test performed on the computer. Change from Baseline, as well as response rates, in variability of response time will be assessed.

  5. Test of Variables of Attention (TOVA) [ Time Frame: 10 weeks ]
    A continuous performance test performed on the computer. Change from Baseline, as well as response rates, in response time will be assessed.

  6. Test of Variables of Attention (TOVA) [ Time Frame: 10 weeks ]
    A continuous performance test performed on the computer. Change from Baseline, as well as response rates, in errors of commission will be assessed.

  7. Test of Variables of Attention (TOVA) [ Time Frame: 10 weeks ]
    A continuous performance test performed on the computer. Change from Baseline, as well as response rates, in errors of omission will be assessed.

  8. Test of Variables of Attention (TOVA) [ Time Frame: 10 weeks ]
    A continuous performance test performed on the computer. Change from Baseline, as well as response rates, in D-prime will be assessed.

  9. Safety as assessed by adverse events (AEs) [ Time Frame: 10 weeks ]
    Any undesirable experience associated with the use of a medical product in a subject

  10. Safety as assessed by body temperature measurements [ Time Frame: 10 weeks ]
    Body temperature measurements as part of vital signs measurements

  11. Safety as assessed by Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: 10 weeks ]
    C-SSRS scale allows investigators to gather lifetime history of suicidality as well as any recent suicidal ideation and/or behavior

  12. Safety as assessed by laboratory tests; blood and urine [ Time Frame: 10 weeks ]
    Laboratory test results (hematology, chemistry and urinalysis).

  13. Safety as assessed by neurological evaluation [ Time Frame: 10 weeks ]
    Neurological evaluation done by investigator

  14. Safety as assessed by Electrocardiogram (ECG) test [ Time Frame: 10 weeks ]
    Analysis and Interpretation of the Electrocardiogram

  15. Safety as assessed by physical examinations [ Time Frame: 10 weeks ]
    Physical examination done by investigator

  16. Safety as assessed by discontinuations due to AEs [ Time Frame: 10 weeks ]
    Discontinuations of subjects due to AEs

  17. Safety as assessed by heart rate measurements [ Time Frame: 10 weeks ]
    Heart rate measurements as part of vital signs measurements

  18. Safety as assessed by respiratory rate measurements [ Time Frame: 10 weeks ]
    Respiratory rate measurements as part of vital signs measurements

  19. Safety as assessed by supine blood pressure [ Time Frame: 10 weeks ]
    Supine blood pressure as part of vital signs measurements



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is a man or a non-pregnant, non-lactating woman 18 to 55 years of age, inclusive, at the Screening visit.
  2. Subject has a diagnosis of ADHD based on criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5) as assessed by the Adult ADHD Clinician Diagnostic Scale, (ACDS Version 1.2) modified for DSM-IV and DSM5 diagnoses; a diagnosis of ADHD not otherwise specified is unacceptable.
  3. Male and Female subjects of childbearing potential must agree to use an effective contraceptive throughout the study
  4. Subject is able to attend the clinic regularly and reliably.
  5. Subject is able to swallow tablets and capsules.
  6. Subject is able to understand, read, write, and speak the local language fluently to complete the study-related materials.
  7. Subject is able to understand and sign an informed consent form to participate in the study.

Exclusion criteria

  1. Subject has any current major psychiatric condition (e.g., schizophrenia, bipolar or personality disorder) or autism spectrum disorder.
  2. Subject has any clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation.
  3. Subject has used an investigational medication/treatment or was enrolled in another clinical trial in the 30 days before the Screening visit.
  4. Subject has used any medication or food supplement that the investigator or the medical monitor consider unacceptable during the 14-day period before the Baseline visit.
  5. Subject's alcohol and caffeine intake will be assessed.
  6. Subject has current suicidality, defined as active ideation, intent or plan, or any significant lifetime suicidal behavior (actual attempt, aborted attempt, interrupted attempt, or act or preparation towards imminently making a suicide attempt). Subjects exhibiting history (within previous 12 months) of non-suicidal self-injurious behavior will be excluded.
  7. Subject has taken any prescription or non-prescription medication for ADHD during the 14 days (or 21 days for atomoxetine) before the Baseline visit. Subjects will not be allowed to take any other medications for ADHD besides the study medication (when prescribed) after the washout period and for the duration of the study, up to and including the safety Follow-up visit. (Other ADHD medications should NOT be prescribed to subjects before completion of the Follow-up visit or Early Termination Visit).
  8. Subject is significantly visually impaired to an extent that is not able to be corrected by prescription glasses or contact lenses.
  9. Subject is closely related to the sponsor, investigator, or study staff. Eligibility of subjects with any relationship to the sponsor, investigator, or study staff will be discussed with the medical monitor before study entry, and the medical monitor will decide on the eligibility of these cases.
  10. Subject has previously been enrolled in an MDX clinical trial.
  11. Subject lives in the same household as another subject in this clinical trial or in another on-going trial with MDX. Subject lives in the same household as someone who has previously participated in a trial with MDX.
  12. Subject has any condition that, in the principal investigator's opinion, would place the subject at risk or influence the conduct of the study or interpretation of results, including (but not limited to) abnormally low intellectual capacity as judged by the investigator.
  13. Subject cannot fully comprehend the implications of the protocol, cannot comply with its requirements, or is incapable of following the study schedule for any reason.
  14. Subject is pregnant, lactating, or using an inadequate contraceptive method. Complete entry criteria will be reviewed and evaluated individually by a protocol trained delegate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02477748


Locations
Show Show 38 study locations
Sponsors and Collaborators
Alcobra Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey Newcorn, MD Icahn School of Medicine at Mount Sinai
Layout table for additonal information
Responsible Party: Alcobra Ltd.
ClinicalTrials.gov Identifier: NCT02477748    
Other Study ID Numbers: AL016
First Posted: June 23, 2015    Key Record Dates
Last Update Posted: January 19, 2017
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperkinesis
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases